Advanced Healing Now Possible (OTC:DSCI)
Michael Vlaicu (September 1st, 2009) Writes:

Derma Sciences, Inc.
(Public, OTC:DSCI)
Derma Sciences is a truly unique and highly undervalued company within the micro-cap biomed space which currently targets a prescription drug market that is about 5x its present market cap. The company is developing a patented topical drug for accelerated healing and scar prevention and newly launched Advanced Wound Care products approaching $10M, including the highly received MEDIHONEY, and BIOGUARD, both of which have garnered tremendeous success and continue to increase sales annually. The real gem however lies within their DSC127 phase II pipeline drug. Derma Sciences reported that it continues to move forward with clinical trials of DSC127, which has the potential to be only the second approved drug on the market for accelerated wound healing, a market with over $100M in sales anually.
About
Derma Sciences, Inc. is a fully integrated manufacturer, marketer and
...amputation, analog, anti-microbial advanced wound care product, California, China, Clinical Nurse Specialist, Contract Manufacturing Services, Derma Sciences Inc., Fda, fungal infection, integrated manufacturer, Johnson & Johnson, launched wound dressing product, Manhasset, Mary Brennan, Michael Vlaicu;, New York, North Shore Long Island Jewish Hospital, pharmaceutical candidate, private label products, products, Q4, Quick-Med Technologies, Regranex and Shire, Renovo, scar, Stocks to Watch, StocksHaven Investments;, strong novel pharmaceutical candidate, Systagenix, Toronto, United Kingdom, United States, University of Southern California, USD, wound-care products


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)





